Costs and margins
No data available for this market
BRIEF: For the three months ended 31 March 2014, Enzon Pharmaceuticals Inc revenues decreased 12% to $9M. Net income increased from $2.4M to $8.5M. Revenues reflect Royalties decrease of 6% to $8.9M, Miscellaneous income decrease of 95% to $31K. Net income reflects Restructuring charges decrease from $2.5M (expense) to $0K, General and administrative decrease of 83% to $508K (expense).